MX2019007608A - Composicion liquida de fibrinogeno humano. - Google Patents
Composicion liquida de fibrinogeno humano.Info
- Publication number
- MX2019007608A MX2019007608A MX2019007608A MX2019007608A MX2019007608A MX 2019007608 A MX2019007608 A MX 2019007608A MX 2019007608 A MX2019007608 A MX 2019007608A MX 2019007608 A MX2019007608 A MX 2019007608A MX 2019007608 A MX2019007608 A MX 2019007608A
- Authority
- MX
- Mexico
- Prior art keywords
- liquid composition
- human fibrinogen
- fibrinogen
- composition
- human
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940106780 human fibrinogen Drugs 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
- 239000004475 Arginine Substances 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención propone una composición farmacéutica que comprende entre 10 y 30 g/l de fibrinógeno, entre 10 y 300 mM de arginina y entre 10 y 300 mM de glutamato. Además el pH de la composición está comprendido entre 6 y 8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1663181A FR3061020B1 (fr) | 2016-12-22 | 2016-12-22 | Composition de fibrinogene humain |
| PCT/FR2017/053839 WO2018115800A1 (fr) | 2016-12-22 | 2017-12-22 | Composition liquide de fibrinogene humain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019007608A true MX2019007608A (es) | 2019-08-29 |
| MX379566B MX379566B (es) | 2025-03-11 |
Family
ID=58358663
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007608A MX379566B (es) | 2016-12-22 | 2017-12-22 | Composicion liquida de fibrinogeno humano |
| MX2021001361A MX2021001361A (es) | 2016-12-22 | 2019-06-21 | Composicion liquida de fibrinogeno humano. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001361A MX2021001361A (es) | 2016-12-22 | 2019-06-21 | Composicion liquida de fibrinogeno humano. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20200093896A1 (es) |
| EP (1) | EP3558381B1 (es) |
| CN (2) | CN117180406A (es) |
| CY (1) | CY1124609T1 (es) |
| DK (1) | DK3558381T3 (es) |
| ES (1) | ES2877848T3 (es) |
| FR (1) | FR3061020B1 (es) |
| HR (1) | HRP20210984T1 (es) |
| HU (1) | HUE055246T2 (es) |
| LT (1) | LT3558381T (es) |
| MX (2) | MX379566B (es) |
| PL (1) | PL3558381T3 (es) |
| PT (1) | PT3558381T (es) |
| RS (1) | RS62103B1 (es) |
| SI (1) | SI3558381T1 (es) |
| SM (1) | SMT202100369T1 (es) |
| WO (1) | WO2018115800A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12030918B2 (en) * | 2019-12-06 | 2024-07-09 | University Of Wyoming | Fibrin particles and methods of forming fibrin particles |
| US20240342253A1 (en) | 2021-08-13 | 2024-10-17 | Biotest Ag | Fibrinogen compositions and methods of preparation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE336207C (de) | 1916-03-05 | 1921-04-28 | Siemens & Halske Akt Ges | Vermittlungsvorrichtung fuer Fernsprechleitungen |
| EP1115745B1 (en) | 1998-09-24 | 2006-05-31 | Pharming Intellectual Property BV | Purification of fibrinogen from fluids by precipitation and hydrophobic interaction chromatography |
| DE69930653T2 (de) | 1998-09-24 | 2007-01-25 | Pharming Intellectual Property Bv | Reinigung von fibrinogen aus milch durch den einsatz von kationenaustauschchromatographie |
| DE10261126A1 (de) * | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
| FR2857267B1 (fr) * | 2003-07-09 | 2006-03-10 | Lab Francais Du Fractionnement | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. |
| FR2887883B1 (fr) | 2005-06-29 | 2007-08-31 | Lab Francais Du Fractionnement | Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines |
| CA2682173C (en) * | 2007-03-22 | 2015-10-27 | Shinichi Miyagawa | Solid fibrinogen preparation |
| EP2987498B1 (en) * | 2008-05-02 | 2017-07-05 | Laboratoire Français du Fractionnement et des Biotechnologies | Treatment of bleeding with low half-life fibrinogen |
| CN101371921B (zh) * | 2008-10-08 | 2013-02-13 | 余美伦 | 一种速溶冻干纤维蛋白原和凝血酶制剂组合物、制备方法及其用途 |
| CN102286095B (zh) * | 2011-07-06 | 2013-08-21 | 大田华灿生物科技有限公司 | 纤维蛋白原的制备方法 |
| KR101127127B1 (ko) * | 2011-10-27 | 2012-03-21 | 주식회사 녹십자 | 고농도 피브리노겐 용액의 제조 방법 및 이를 이용한 피브린 실란트 제품의 제조방법 |
| FR3018450B1 (fr) | 2014-03-11 | 2016-04-15 | Lab Francais Du Fractionnement | Procede de preparation de proteines plasmatiques humaines |
-
2016
- 2016-12-22 FR FR1663181A patent/FR3061020B1/fr active Active
-
2017
- 2017-12-22 SI SI201730821T patent/SI3558381T1/sl unknown
- 2017-12-22 US US16/471,869 patent/US20200093896A1/en not_active Abandoned
- 2017-12-22 HR HRP20210984TT patent/HRP20210984T1/hr unknown
- 2017-12-22 WO PCT/FR2017/053839 patent/WO2018115800A1/fr not_active Ceased
- 2017-12-22 HU HUE17837979A patent/HUE055246T2/hu unknown
- 2017-12-22 LT LTEP17837979.8T patent/LT3558381T/lt unknown
- 2017-12-22 EP EP17837979.8A patent/EP3558381B1/fr active Active
- 2017-12-22 PL PL17837979T patent/PL3558381T3/pl unknown
- 2017-12-22 PT PT178379798T patent/PT3558381T/pt unknown
- 2017-12-22 SM SM20210369T patent/SMT202100369T1/it unknown
- 2017-12-22 ES ES17837979T patent/ES2877848T3/es active Active
- 2017-12-22 CN CN202311177586.4A patent/CN117180406A/zh active Pending
- 2017-12-22 MX MX2019007608A patent/MX379566B/es unknown
- 2017-12-22 RS RS20210796A patent/RS62103B1/sr unknown
- 2017-12-22 CN CN201780078234.XA patent/CN110087689B/zh active Active
- 2017-12-22 DK DK17837979.8T patent/DK3558381T3/da active
-
2019
- 2019-06-21 MX MX2021001361A patent/MX2021001361A/es unknown
-
2021
- 2021-07-06 CY CY20211100606T patent/CY1124609T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117180406A (zh) | 2023-12-08 |
| PT3558381T (pt) | 2021-07-01 |
| PL3558381T3 (pl) | 2021-10-25 |
| FR3061020B1 (fr) | 2019-05-17 |
| EP3558381B1 (fr) | 2021-04-07 |
| CN110087689B (zh) | 2023-09-29 |
| MX379566B (es) | 2025-03-11 |
| HRP20210984T1 (hr) | 2021-09-17 |
| HUE055246T2 (hu) | 2021-11-29 |
| CY1124609T1 (el) | 2022-07-22 |
| MX2021001361A (es) | 2021-04-13 |
| FR3061020A1 (fr) | 2018-06-29 |
| US20200093896A1 (en) | 2020-03-26 |
| ES2877848T3 (es) | 2021-11-17 |
| EP3558381A1 (fr) | 2019-10-30 |
| LT3558381T (lt) | 2021-08-10 |
| CN110087689A (zh) | 2019-08-02 |
| DK3558381T3 (da) | 2021-06-28 |
| WO2018115800A1 (fr) | 2018-06-28 |
| SI3558381T1 (sl) | 2021-11-30 |
| RS62103B1 (sr) | 2021-08-31 |
| SMT202100369T1 (it) | 2021-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013841A (es) | Inhibidores de la interaccion de menina-mll. | |
| MX2023002982A (es) | Inhibidores de la interaccion de menina-leucemia de linaje mixto. | |
| MX2018007703A (es) | Inhibidores de la interaccion de menina-linaje leucemico mixto. | |
| MA43187B1 (fr) | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations | |
| MX390806B (es) | Proteasa de cisteina. | |
| WO2018075692A3 (en) | Antibody constructs | |
| MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
| MY187486A (en) | Cysteine protease | |
| MX388858B (es) | Reducción de la viscosidad de formulaciones farmacéuticas | |
| BR112018075140A2 (pt) | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| MX392199B (es) | Composiciones farmaceuticas para terapia de combinacion | |
| MX2017003121A (es) | Formulaciones de anticuerpos. | |
| EA201692031A1 (ru) | Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| MX389320B (es) | Anticuerpos anti-tnfrsf25 | |
| MX2018000570A (es) | Nuevas isoformas de tripsina y su uso. | |
| MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
| EA201891608A1 (ru) | Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана | |
| MX2017000676A (es) | Oritavancina de alta pureza y metodo para producir la misma. | |
| AR104591A1 (es) | Piroglutamato de vortioxetina | |
| TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
| MY195945A (en) | Ras Protein Degradation Inducing Molecule and Pharmaceutical Composition | |
| MX2021001361A (es) | Composicion liquida de fibrinogeno humano. | |
| MX379715B (es) | 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso. |